Cryptococcal pneumonia in a patient with rheumatoid arthritis treated with baricitinib

Dear Editor, Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor approved for treating patients with RA who have had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [1], and has been investigated in clinical trials for the treatment of autoimmune diseases. However, there is a safety issue with regard to the risk of serious and opportunistic infections in patients using JAK...